✉news HealthMedicine first seen 5 h ago, last 2 h ago, peak #27
Eli Lilly's Next Weight-Loss Drug Touted as Potential Blockbuster
Original: Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet
Eli Lilly is promoting a new weight-loss drug in development that analysts suggest could surpass Zepbound, the company's current blockbuster, in sales. The claim comes from market commentary arguing that the next-generation therapy could become the company's biggest product yet, as competition in the obesity drug market intensifies and demand for effective treatments keeps growing.
Why now: Investors and health watchers are closely following Eli Lilly's obesity drug pipeline amid the booming weight-loss treatment market.
Rank over time, top of the chart is #1. 3 snapshots from 5 h ago to 2 h ago.
Evidence
- Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet · The Globe and Mail
- Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet · theglobeandmail.com
API: https://socialmediatrends-api.osmike.com/v1/trends/995214